Search


	Podcast:		OncLive® On Air
	Episode:		43: FDA Approval Insights: Tazemetostat in Relapsed/Refractory Follicular Lymphoma
	Category:		Science & Medicine
	Duration:		00:09:35
	Publish Date:		2020-10-01 19:56:13
	Description:		In our exclusive interview, Dr. Leonard discusses the FDA approval of tazemetostat in patients with relapsed/refractory follicular lymphoma whose tumors are EZH2 positive, as well as those with relapsed/refractory follicular lymphoma who have no other available satisfactory treatment options, and the benefits of providing another agent for this subset of patients.
	Total Play:		0